Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT
Stopped early · Phase 1
Conditions studied: AML/MDS
In brief
This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT.
Key facts
- Study ID
- NCT04679194
- Run by
- Mana Therapeutics
- People needed
- 11
- Starts
- 2020-12-08
- Expected to finish
- 2023-03-28
- Last updated by the study team
- 2023-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Colorado Blood Cancer Institute — Denver, Colorado, United States
- Northside Hospital - Atlanta — Atlanta, Georgia, United States
- University of Kansas Cancer Center — Kansas City, Kansas, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Tennessee Oncology — Nashville, Tennessee, United States
- Vanderbilt - Ingram Cancer Center — Nashville, Tennessee, United States
- Texas Transplant/St David's South Austin — Austin, Texas, United States
- Texas Transplant/Methodist Hospital — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.